Journal Article Review Ppublish
PubMed: 40268657 DOI: 10.1016/j.it.2025.03.004
mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation.
Trends Immunol 46(5):357-360
Authors: Byron Brook, Morgan Goetz, Valerie Duval, Romain Micol, David J Dowling
Affiliations
- Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
- Combined Therapeutics Incorporated, Boston, MA 02135, USA.
- Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Abstract
The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based biodistribution control of encoded transcripts, and precision adjuvantation strategies.
MeSH
Vaccines, Micrornas, Rna, Messenger, Immunity, Mrna Vaccines, Lipid Nanoparticles